Cannabis compounds may reduce symptoms for some disorders, but evidence quality is low ...

Many hospitalized adults could benefit from linkage to dental care. This article describes a planned study to refer inpatients to community dental providers. Objectives: Previous research suggests ...

And thanks for Stifel for having us here this afternoon. So yes, if I look at 2026 as we exited the prior year, we're entering this year, with a great deal of enterprise-wide momentum, and this comes ...

Harrow, Inc. is rapidly evolving into a dominant US ophthalmic pharma player, with a 30-fold revenue increase since 2015 and ...

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the 'Company'), a clinical-stage biopharmaceutical company focused on its Phase ...

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01 ...

Elevated blood pressure (hypertension) is a leading, preventable risk factor for heart disease. Nicotinamide mononucleotide ...

Throughout the year, the Company reported significant positive preclinical findings for SIL204 across eight KRAS mutations and four cancer types, including first evidence of activity in gastric cancer ...

Epilepsy is one of the common disorders known to man, with early accounts of the disorder traced back to antiquity.1 It was ...

Achieved randomization target of 230 patients in LEVEL study, topline data expected in third quarter of 2026 Initiated global Phase 3 LEVEL-2 clinical trial and opened long-term OLE study for patients ...